Navigation Links
Merck Serono Launches Strategic Venture Capital Fund
Date:3/23/2009

- New Venture Capital Fund Will Invest in Biotech Start-up Companies Focused on Merck Serono's Core Therapeutic Areas

GENEVA, March 23 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the formation of 'Merck Serono Ventures', a strategic, corporate venture capital fund to invest in emerging biotechnology companies. The fund will support biotech start-up companies that have the potential to provide innovative products in Merck Serono's core therapeutic areas, in particular in Neurodegenerative Diseases, Oncology and Autoimmune & Inflammatory Diseases. 'Merck Serono Ventures' also will target companies developing innovative technologies that could enable the discovery and development of new products in Merck Serono's core therapeutic areas.

"Biotech start-up companies are an important element in scientific innovation," said Bernhard Kirschbaum, Executive Vice President of Research & Development at Merck Serono. "Merck Serono's venture capital fund will provide the opportunity to support scientific excellence in our core fields of interest and provide start-up companies with the opportunity to interact early on with our organization."

"The creation of a venture capital fund underlines our commitment to be Best Partner for biotech entrepreneurs and their investors," said Vincent Aurentz, Executive Vice President of Portfolio Development at Merck Serono. "This activity complements our toolkit of collaborative approaches to build a high-quality portfolio with our partners."

'Merck Serono Ventures' has an initial commitment to invest up to EUR 40 million during the next five years. A key component of Merck Serono's strategy to be recognized as the 'Best Partner' in the biopharmaceutical industry, 'Merck Serono Ventures' will be included in the company's Portfolio Development function and closely linked to the Research & Deve
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
2. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
3. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
4. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
5. Merck Serono Named as a Top Employer by Science Magazine
6. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
7. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
8. BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance
9. New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
10. Merck & Co., Inc. Named Keynote Sponsor For Diversity Alliance For Sciences Inaugural Conference
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... February 28, 2015 Increasing its efforts to ... launches its first three episodes of The GMO TRUTH podcast ... this month, as it continues its mission to discover the ... project's first phase, to “uncover the truth about the GMOs ... , The GMO Truth Podcast is an expansion of the ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... financial results for the quarter,ended March 31, 2008., ... net revenue of,$372.2 million compared to net revenue of ... increase was primarily due to increased,product and service revenue ...
... dynamic stabilization,nonfusion segments skyrocketed, according to Millennium Research Group,s US ... ... Millennium Research Group,s,(MRG) US Spine Marketrack(TM) results indicate that ... and surgeon,awareness and new product releases starting in Q3 2007 ...
... will be enrolled to evaluate R7128 1500mg BID in HCV,genotypes 2 and 3 prior ... ... 1:00 PM ET (US) ... CEST (Milan) --, PRINCETON, N.J. and MILAN, Italy, April 24 ,Pharmasset, Inc. (Nasdaq: ...
Cached Biology Technology:Inverness Medical Innovations Announces First Quarter 2008 Results 2Inverness Medical Innovations Announces First Quarter 2008 Results 3Inverness Medical Innovations Announces First Quarter 2008 Results 4Inverness Medical Innovations Announces First Quarter 2008 Results 5Inverness Medical Innovations Announces First Quarter 2008 Results 6Inverness Medical Innovations Announces First Quarter 2008 Results 7Inverness Medical Innovations Announces First Quarter 2008 Results 8Inverness Medical Innovations Announces First Quarter 2008 Results 9Inverness Medical Innovations Announces First Quarter 2008 Results 10Adoption of Spinal Nonfusion Technologies Doubled in One Year 2Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 2Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 3Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 4Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study 5
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... standing member of the IOF Board and leading researcher ... the recipient of the prestigious Pierre Delmas Award. The ... Osteoporosis & Osteoarthritis (ESCEO13-IOF), currently being held in Rome, ... Osteoporosis Foundation (IOF) in memory of Pierre D. Delmas, ...
... the University of Alberta are abuzz after using fruit ... caffeine,s lethal effects on cancer cellsresults that could one ... Previous research has established that caffeine interferes with ... finding that has generated interest in using the stimulant ...
... past, now has had its genome sequenced, providing a ... the adaptation from an aquatic environment to land. A ... Director of Molecular Genetics at the Benaroya Research Institute ... the University of Washington, will publish "The African coelacanth ...
Cached Biology News:Pierre Delmas Award presented in Rome to Professor Socrates Papapoulos 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 3
... the macro- and micronutrients as ... (1962) and the vitamins as ... (1968). Preparation Quantity Equivalency: Formulated ... powder per liter of medium. ...
... Total Canine Endostatin. Canine Cytokine ... products include a line of enzyme-linked ... reagents used for multiple research applications. ... are ultra-sensitive, quick and dependable assays. ...
... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
... Biosystems and MDS Sciex present the ... high performance hybrid triple quadrupole/linear ion ... discovery, drug development or proteomics researcher. ... from the leaders in mass spectrometry ...
Biology Products: